1
|
Fontaine C, Van den Eynden G, de Wind R, Boisson A, Renard V, Van den Bulck H, Vuylsteke P, Glorieux P, Dopchie C, Decoster L, De Grève J, Awada A, Wildiers H, Willard-Gallo K. Abstract P2-08-47: Evaluation of stromal tumor-infiltrating lymphocytes (sTIL) and tertiary lymphoid structures (TLS) in early breast cancer patients with triple negative breast cancer(TNBC) included in a prospective study of neoadjuvant chemotherapy (NAC) with Epirubicin and cyclophosphamide (EC) and carboplatin-paclitaxel (PC) (BSMO 2014-01). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p2-08-47] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: BSMO 2014-01 is a completed prospective phase 2 study evaluating the efficacy of neoadjuvant EC and PC. One of the secondary endpoints was the correlation of sTIL with response, pCR and survival. We also assessed the relationship between sTIL and TLS in the diagnostic biopsies.
Methods: Stromal TIL (sTIL) were evaluated on H&E stained tumor biopsies before the start of the NAC according to the criteria described by Salgado et al(1). Scores were defined as "low" or "high" if lymphocytic infiltration in the stroma around the tumor was ≤ 10% or > 10%. TLS are ectopic lymph node-like structures recently identified in breast cancer. TLS were counted using a dual IHC stain for CD3 (T cells) and CD20 (B cells) and categorized as "little" if the TLS occupied < 10% or "moderate to abundant" if they occupied ≥ 10% of the adjacent tissue. The correlation between sTIL and pathologic parameters was analyzed using the chi-square test; DFS and OS between the groups was estimated by using the log-rank test.
Results: So far we could quantify the number of sTIL in 38 out of 63 TNBC pts treated with neoadjuvant EC-PC. Twenty eight pts had a high sTIL score and 10 pts had a low sTIL score. The high-sTIL group (19/28) achieved a numerical higher pathologic complete remission (pCR) rate than the low-sTIL group (5/10) (p=0.3); both groups had a comparable disease free survival of 28.6 mths and 26.7 mths respectively (p=0.7). The overall survival was similar:29 mths and 27.8 mths respectively (p=0.8). Stromal TLS were identified in 10 out 23 samples available for this analysis and we could demonstrate a positive correlation between high levels of sTIL and high levels of moderate to abundant TLS(CD3) in the adjacent tissue in six out of the ten samples in which TLS were present (p=0.1).
Conclusion: These preliminary results could not confirm the results published by Denkert et al earlier this year(2). A trend for correlation of the presence of high sTIL with moderate to abundant levels of TLS was found. Analysis on the remaining samples of all patients included in the study and correlation with outcome is ongoing and these completed results will be presented.
(1)Assessing Tumor-infiltrating lymphocytes in solid tumors. Hendry S, Salgado R et al. Adv Anat Pathol 2017; 235-251.
(2)Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer. Denkert C et al. Lancet Oncol 2018; 40-50.
Citation Format: Fontaine C, Van den Eynden G, de Wind R, Boisson A, Renard V, Van den Bulck H, Vuylsteke P, Glorieux P, Dopchie C, Decoster L, De Grève J, Awada A, Wildiers H, Willard-Gallo K. Evaluation of stromal tumor-infiltrating lymphocytes (sTIL) and tertiary lymphoid structures (TLS) in early breast cancer patients with triple negative breast cancer(TNBC) included in a prospective study of neoadjuvant chemotherapy (NAC) with Epirubicin and cyclophosphamide (EC) and carboplatin-paclitaxel (PC) (BSMO 2014-01) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-08-47.
Collapse
Affiliation(s)
- C Fontaine
- UZ Brussel, Jette, Belgium; Institut Jules Bordet, Brussels, Belgium; UZ Leuven, Leuven, Belgium; BSMO, Brussels, Belgium
| | - G Van den Eynden
- UZ Brussel, Jette, Belgium; Institut Jules Bordet, Brussels, Belgium; UZ Leuven, Leuven, Belgium; BSMO, Brussels, Belgium
| | - R de Wind
- UZ Brussel, Jette, Belgium; Institut Jules Bordet, Brussels, Belgium; UZ Leuven, Leuven, Belgium; BSMO, Brussels, Belgium
| | - A Boisson
- UZ Brussel, Jette, Belgium; Institut Jules Bordet, Brussels, Belgium; UZ Leuven, Leuven, Belgium; BSMO, Brussels, Belgium
| | - V Renard
- UZ Brussel, Jette, Belgium; Institut Jules Bordet, Brussels, Belgium; UZ Leuven, Leuven, Belgium; BSMO, Brussels, Belgium
| | - H Van den Bulck
- UZ Brussel, Jette, Belgium; Institut Jules Bordet, Brussels, Belgium; UZ Leuven, Leuven, Belgium; BSMO, Brussels, Belgium
| | - P Vuylsteke
- UZ Brussel, Jette, Belgium; Institut Jules Bordet, Brussels, Belgium; UZ Leuven, Leuven, Belgium; BSMO, Brussels, Belgium
| | - P Glorieux
- UZ Brussel, Jette, Belgium; Institut Jules Bordet, Brussels, Belgium; UZ Leuven, Leuven, Belgium; BSMO, Brussels, Belgium
| | - C Dopchie
- UZ Brussel, Jette, Belgium; Institut Jules Bordet, Brussels, Belgium; UZ Leuven, Leuven, Belgium; BSMO, Brussels, Belgium
| | - L Decoster
- UZ Brussel, Jette, Belgium; Institut Jules Bordet, Brussels, Belgium; UZ Leuven, Leuven, Belgium; BSMO, Brussels, Belgium
| | - J De Grève
- UZ Brussel, Jette, Belgium; Institut Jules Bordet, Brussels, Belgium; UZ Leuven, Leuven, Belgium; BSMO, Brussels, Belgium
| | - A Awada
- UZ Brussel, Jette, Belgium; Institut Jules Bordet, Brussels, Belgium; UZ Leuven, Leuven, Belgium; BSMO, Brussels, Belgium
| | - H Wildiers
- UZ Brussel, Jette, Belgium; Institut Jules Bordet, Brussels, Belgium; UZ Leuven, Leuven, Belgium; BSMO, Brussels, Belgium
| | - K Willard-Gallo
- UZ Brussel, Jette, Belgium; Institut Jules Bordet, Brussels, Belgium; UZ Leuven, Leuven, Belgium; BSMO, Brussels, Belgium
| |
Collapse
|
2
|
Fontaine C, Cappoen N, Renard V, Vuylsteke P, Van Den Bulck H, Glorieux P, t'Kint de Roodenbeke D, Dopchie C, Decoster L, Vanacker L, De Grève J, Awada A, Wildiers H. Abstract P5-16-06: Neoadjuvant weekly carboplatin and paclitaxel followed by dose dense epirubicin and cyclophosphamide in triple negative breast cancer patients: A single arm phase II study from the Belgian Society of Medical Oncology. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-16-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Triple negative breast cancer (TNBC) remains a challenging disease with dismal prognosis. Platinum analogs have not yet shown to improve long term outcome in this setting, but are associated with increased pathological complete response rate (pCR) at the cost of higher toxicity.
Aim: To further increase or maintain the high pCR rate with platinum containing schedules while decreasing toxicity by administering low dose weekly carboplatin instead of high-dose 3 weekly carboplatin as in CALGB 40603.(1)
Patients and methods: We evaluated the tolerability and the impact of the addition of weekly carboplatin (CP) to paclitaxel (P) and dose dense epirubicin-cyclofosfamide (EC) on pCR in an open-label multicenter phase II study in stage II/III TNBC patients (pts). Sixty three pts received dose dense paclitaxel (P:80mg/m2/wk) concurrent with carboplatin (CP: AUC=2) for 12 wks, followed by two-weekly epirubicin (E:90mg/m2) and cyclophosphamide (C:600mg/m2) for 4 cycles. The primary endpoint is pCR in the breast and axilla. Additionally treatment deliveryand adverse events are recorded. A correlative assessment of germline mutations in homologous recombination (HR) genes is planned. Pts are monitored for response by magnetic resonance and mammography and also for relapse free survival and time to treatment failure. The study size sample has been calculated according to the optimal Simon's two-stage design method. The target sample size was 63 patients with 80% power to detect a pCR rate of ≥47% (α= 0.05).
Results: Accrual to the study is completed with 63 eligible pts with operable, noninflammatory stage II and III TNBC included. Most patients were between 40 and 60 yrs old and were clinical stageT2 tumors. Half of the pts were clinically node + and 70% were G3. Sixty six percent had breast conserving surgery. Sixteen out of 26 (61.5%) of the currently evaluable pts achieved a pCR rate in the breast and axilla. The other ongoing patients have not yet reached this endpoint. Four out of 21 evaluable pts that completed the chemotherapy missed two or more doses of CP due to neutropenia(NP) G3/4(2), general deterioration G3(1) and polyneuropathy(PNP) G3(1) and seven pts needed one dose reduction of P and/or CP due to NP G3-4 (3-2) and PNP G2(1) and one abdominal infection.
Conclusion: These preliminary data suggest that the addition of weekly carboplatinum to neoadjuvant paclitaxel and EC is feasible and has a promising pCR rate in the breast and axilla as high as 61.5% in early TNBC pts. More mature toxicity and outcome data and correlation with genome analysis will be presented.
(1) Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once per week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603(Alliance) Sikov WM et al. J Clin Oncol 33:13-21; 2014.
Citation Format: Fontaine C, Cappoen N, Renard V, Vuylsteke P, Van Den Bulck H, Glorieux P, t'Kint de Roodenbeke D, Dopchie C, Decoster L, Vanacker L, De Grève J, Awada A, Wildiers H. Neoadjuvant weekly carboplatin and paclitaxel followed by dose dense epirubicin and cyclophosphamide in triple negative breast cancer patients: A single arm phase II study from the Belgian Society of Medical Oncology [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-16-06.
Collapse
Affiliation(s)
- C Fontaine
- UZ Brussel, Jette, Brussels, Belgium; University Hospitals Leuven, Leuven, Belgium; Belgian Society of Medical Oncology (BSMO), Jette, Brussels, Belgium; Jules Bordet Institute, Brussels, Belgium
| | - N Cappoen
- UZ Brussel, Jette, Brussels, Belgium; University Hospitals Leuven, Leuven, Belgium; Belgian Society of Medical Oncology (BSMO), Jette, Brussels, Belgium; Jules Bordet Institute, Brussels, Belgium
| | - V Renard
- UZ Brussel, Jette, Brussels, Belgium; University Hospitals Leuven, Leuven, Belgium; Belgian Society of Medical Oncology (BSMO), Jette, Brussels, Belgium; Jules Bordet Institute, Brussels, Belgium
| | - P Vuylsteke
- UZ Brussel, Jette, Brussels, Belgium; University Hospitals Leuven, Leuven, Belgium; Belgian Society of Medical Oncology (BSMO), Jette, Brussels, Belgium; Jules Bordet Institute, Brussels, Belgium
| | - H Van Den Bulck
- UZ Brussel, Jette, Brussels, Belgium; University Hospitals Leuven, Leuven, Belgium; Belgian Society of Medical Oncology (BSMO), Jette, Brussels, Belgium; Jules Bordet Institute, Brussels, Belgium
| | - P Glorieux
- UZ Brussel, Jette, Brussels, Belgium; University Hospitals Leuven, Leuven, Belgium; Belgian Society of Medical Oncology (BSMO), Jette, Brussels, Belgium; Jules Bordet Institute, Brussels, Belgium
| | - D t'Kint de Roodenbeke
- UZ Brussel, Jette, Brussels, Belgium; University Hospitals Leuven, Leuven, Belgium; Belgian Society of Medical Oncology (BSMO), Jette, Brussels, Belgium; Jules Bordet Institute, Brussels, Belgium
| | - C Dopchie
- UZ Brussel, Jette, Brussels, Belgium; University Hospitals Leuven, Leuven, Belgium; Belgian Society of Medical Oncology (BSMO), Jette, Brussels, Belgium; Jules Bordet Institute, Brussels, Belgium
| | - L Decoster
- UZ Brussel, Jette, Brussels, Belgium; University Hospitals Leuven, Leuven, Belgium; Belgian Society of Medical Oncology (BSMO), Jette, Brussels, Belgium; Jules Bordet Institute, Brussels, Belgium
| | - L Vanacker
- UZ Brussel, Jette, Brussels, Belgium; University Hospitals Leuven, Leuven, Belgium; Belgian Society of Medical Oncology (BSMO), Jette, Brussels, Belgium; Jules Bordet Institute, Brussels, Belgium
| | - J De Grève
- UZ Brussel, Jette, Brussels, Belgium; University Hospitals Leuven, Leuven, Belgium; Belgian Society of Medical Oncology (BSMO), Jette, Brussels, Belgium; Jules Bordet Institute, Brussels, Belgium
| | - A Awada
- UZ Brussel, Jette, Brussels, Belgium; University Hospitals Leuven, Leuven, Belgium; Belgian Society of Medical Oncology (BSMO), Jette, Brussels, Belgium; Jules Bordet Institute, Brussels, Belgium
| | - H Wildiers
- UZ Brussel, Jette, Brussels, Belgium; University Hospitals Leuven, Leuven, Belgium; Belgian Society of Medical Oncology (BSMO), Jette, Brussels, Belgium; Jules Bordet Institute, Brussels, Belgium
| |
Collapse
|
3
|
Essola B, Malvaux P, Landenne J, Kargar S, Dopchie C, Waignein F, Sleiman WB, Hauters P. [Gallbladder metastasis from breast carcinoma: a new case report]. Rev Med Brux 2012; 33:171-175. [PMID: 22891589] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
The breast carcinoma metastases preferentially in the axillary lymph nodes, bones, lungs, liver and soft tissues. Gastrointestinal or bladder dissemination is very rare. We report the case of a 63-year-old female with a clinical presentation of acute cholecystitis, who underwent laparoscopic cholecystectomy in emergency. The gallbladder showed a nodule at the infundibulum, which was responsible for the gallbladder hydrops with macroscopic features of a cholangiocarcinoma. Histological examination disclosed a metastasis from a lobular breast carcinoma with positive hormone receptors, but no overexpression of the Neu oncogene. Immunohistochemistry showed positive staining for cytokeratin7 suggesting a lesion of breast origin. The absence of E-cadherin was consistent with lobular carcinoma while negative CA 19.9 excluded cholangiocarcinoma. The patient had received 15 years previously a right mastectomy with axillary dissection followed by chemotherapy and radiotherapy for breast carcinoma of ductal type labeled SBR stage III, pT3N1 M0, showing hormone receptors but absent Neu oncogene. Proofreading of the mastectomy histological slide concluded that it was a lobular rather than a ductal type carcinoma, confirming the finding of a gallbladder metastasis 15 years after the mastectomy. The patient showed no local recurrence or contralateral lesions on magnetic resonance imaging (MRI). The bone scan showed metastases in the skull, scapula, right rib cage, thoracolumbar spine and pelvis, also confirmed by MRI. A treatment with exemestane and zoledronic acid was introduced. The follow-up at 6 months showed regression of the bone lesions and absence of parenchymal new locations.
Collapse
Affiliation(s)
- B Essola
- Services de Chirurgie Digestive, Centre Hospitalier de Wallonie Picarde, Site Notre-Dame, Tournai.
| | | | | | | | | | | | | | | |
Collapse
|
4
|
Seront E, Rottey S, Sautois B, Kerger J, D'Hondt LA, Verschaeve V, Canon JL, Dopchie C, Vandenbulcke JM, Whenham N, Goeminne JC, Clausse M, Verhoeven D, Glorieux P, Branders S, Dupont P, Schoonjans J, Feron O, Machiels JP. Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann Oncol 2012; 23:2663-2670. [PMID: 22473592 DOI: 10.1093/annonc/mds057] [Citation(s) in RCA: 109] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
Abstract
BACKGROUND This phase II study assessed the safety and efficacy of everolimus, an oral mammalian target of rapamycin inhibitor in advanced transitional carcinoma cell (TCC) after failure of platinum-based therapy. PATIENTS AND METHODS Thirty-seven patients with advanced TCC received everolimus 10 mg/day until progressive disease (PD) or unacceptable toxicity. The primary end point was the disease control rate (DCR), defined as either stable disease (SD), partial response (PR), or complete response at 8 weeks. Angiogenesis-related proteins were detected in plasma and changes during everolimus treatment were analyzed. PTEN expression and PIK3CA mutations were correlated to disease control. RESULTS Two confirmed PR and eight SD were observed, resulting in a DCR of 27% at 8 weeks. Everolimus was well tolerated. Compared with patients with noncontrolled disease, we observed in patients with controlled disease a significant higher baseline level of angiopoietin-1 and a significant early plasma decrease in angiopoietin-1, endoglin, and platelet-derived growth factor-AB. PTEN loss was observed only in patients with PD. CONCLUSIONS Everolimus showed clinical activity in advanced TCC. The profile of the plasma angiogenesis-related proteins suggested a role of the everolimus antiangiogenic properties in disease control. PTEN loss might be associated with everolimus resistance.
Collapse
Affiliation(s)
- E Seront
- Department of Medical Oncology, Centre du Cancer, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Brussels; Angiogenesis and Cancer Research Laboratory, Pole of Pharmacology and Therapeutics, Université catholique de Louvain, Brussels
| | - S Rottey
- Department of Medical Oncology, University Hospital Gent, Gent
| | - B Sautois
- Department of Medical Oncology, Centre Hospitalier Universitaire Sart-Tilman, Liège
| | - J Kerger
- Department of Medical Oncology, Centre Hospitalier Universitaire Mont-Godinne, Namur
| | - L A D'Hondt
- Department of Medical Oncology, Centre Hospitalier Universitaire Mont-Godinne, Namur
| | - V Verschaeve
- Department of Medical Oncology, Grand Hôpital de Charleroi, Charleroi
| | - J-L Canon
- Department of Medical Oncology, Grand Hôpital de Charleroi, Charleroi
| | - C Dopchie
- Department of Medical Oncology, Réseau Hospitalier de Médecine Sociale, Tournai
| | - J M Vandenbulcke
- Department of Medical Oncology, Réseau Hospitalier de Médecine Sociale, Tournai
| | - N Whenham
- Department of Medical Oncology, Clinique Saint-Pierre Ottignies, Ottignies
| | - J C Goeminne
- Department of Medical Oncology, Centre de Maternité Saint Elisabeth, Namur
| | - M Clausse
- Department of Medical Oncology, Clinique Saint-Luc, Bouge
| | - D Verhoeven
- Department of Medical Oncology, AZ Klina, Braschaat
| | - P Glorieux
- Department of Medical Oncology, Clinique Saint Joseph, Arlon
| | - S Branders
- Machine Learning Group, Institute of Information and Communication Technologies, Electronics and Applied Mathematics, Université catholique de Louvain, Louvain-la-Neuve
| | - P Dupont
- Machine Learning Group, Institute of Information and Communication Technologies, Electronics and Applied Mathematics, Université catholique de Louvain, Louvain-la-Neuve
| | - J Schoonjans
- Department of radiology, Centre Hospitalier de Jolimont, Haine Saint Paul, Belgium
| | - O Feron
- Angiogenesis and Cancer Research Laboratory, Pole of Pharmacology and Therapeutics, Université catholique de Louvain, Brussels
| | - J-P Machiels
- Department of Medical Oncology, Centre du Cancer, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Brussels.
| |
Collapse
|
5
|
de Jongh E, van Brummelen D, van Warmerdam L, Fontaine C, Dopchie C, Vos A, Janssens J, Erdkamp F. Abstract P6-11-08: A Comparison of Chemotherapeutic Treatment Practice in Metastatic Breast Cancer (MBC) in Belgium (BE) and The Netherlands (NL). Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p6-11-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Current treatment recommendations provide limited guidance for chemotherapy (CT) of MBC, while physicians have many options to choose from. We undertook a retrospective survey to describe and compare actual CT approaches to MBC in clinical practice in two neighboring European countries, BE and NL.
Methods: 20 BE and 18 NL hospitals collected data for 490 and 434 patients (pts), respectively, diagnosed with MBC in 2003-2009 and treated with ≥1 CT regimen. Demographic, disease and treatment data of the last 25 consecutively treated pts per hospital were included in each survey. The NL survey required age ≥70 yrs at MBC diagnosis, the BE survey had no upper age limit. We compared patient characteristics and treatment policies between both cohorts (BE vs. NL, for all comparisons). Results: BE patients were older at MBC diagnosis (median 60 vs. 56 yrs) and had M1 tumor status at primary diagnosis more frequently (26 vs. 20%). Average year of MBC diagnosis was 2005 for both countries. There were no striking differences in ER/PR positivity (61/50 vs. 64/47%), HER2/neu overexpression (27 vs. 31%), triple negative status (12 vs. 15%), or cardiac co-morbidity. Prior hormonal (22 vs. 12%), hormonal + adjuvant CT (32 vs. 26%), and total adjuvant CT (58 vs. 51%) had been given more frequently in the BE cohort. In pts receiving adjuvant CT, anthracyclines had been used more frequently in the NL cohort (61 vs. 78%). Pts in the BE and NL cohort received up to 10 and 6 lines of CT, respectively. 79 vs. 73% and 55 vs. 43% of pts received 2 and 3 lines of CT, respectively. BE pts received far more monotherapy in first line (46 vs. 25%), but not in second (66 vs. 65%) and third line (65 vs. 63%). Drugs used most frequently for monotherapy in lines 1-3 were the same in BE and NL: docetaxel (40 vs. 38%) and capecitabine (13 vs. 26%) in line 1; docetaxel (27 vs. 38%) and capecitabine (23 vs. 16%) in line 2; capecitabine (30 vs. 30%) and vinorelbine (16 vs. 19%) in line 3. The most frequently used CT combinations were very different: FEC (40%)vs. FAC (24%) in first line, FEC (7%) vs. CMF (14%) in second line, and non-pegylated liposomal doxorubicin/cyclophosphamide (6%) vs. CMF (15%) in third line.
Many different CT regimens for MBC were used throughout all lines (e.g. > 20 regimens in first line) in both countries. Overall, 81 vs. 71% of pts received a taxane and/or an anthracycline in first line, 57 vs. 60% in second line, and 43 vs. 29% in third line. 33 vs. 36% were re-challenged with an anthracycline after having received anthracycline-based (neo) adjuvant CT.
Physician-assessed response (52 vs. 53%) and stable disease rates (22 vs. 26%) to first-line CT were similar.
Conclusions: Daily treatment practice of MBC differs considerably between BE and NL, in particular with respect to monotherapy vs. combination CT in first line, specific combination regimens used in lines 1-3, and the number of subsequent lines employed. More adjuvant treatment appeared to have been given to Belgian pts. Despite these differences, reported response rates were remarkably similar. Although a wide variety of CT regimens are used in MBC in BE and NL, anthracyclines and taxanes are the cornerstones in both countries.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P6-11-08.
Collapse
Affiliation(s)
- E de Jongh
- Zaans Medisch Centrum, Zaandam, Netherlands; Universitair Ziekenhuis Brussel, Belgium; Catharina Ziekenhuis, Eindhoven, Netherlands; Clinique Notre Dame, Tournai, Belgium; Ziekenhuis Bernhoven, Oss, Netherlands; Salvatorziekenhuis, Hasselt, Belgium; Orbis Medisch Centrum, Sittard, Netherlands
| | - D van Brummelen
- Zaans Medisch Centrum, Zaandam, Netherlands; Universitair Ziekenhuis Brussel, Belgium; Catharina Ziekenhuis, Eindhoven, Netherlands; Clinique Notre Dame, Tournai, Belgium; Ziekenhuis Bernhoven, Oss, Netherlands; Salvatorziekenhuis, Hasselt, Belgium; Orbis Medisch Centrum, Sittard, Netherlands
| | - L van Warmerdam
- Zaans Medisch Centrum, Zaandam, Netherlands; Universitair Ziekenhuis Brussel, Belgium; Catharina Ziekenhuis, Eindhoven, Netherlands; Clinique Notre Dame, Tournai, Belgium; Ziekenhuis Bernhoven, Oss, Netherlands; Salvatorziekenhuis, Hasselt, Belgium; Orbis Medisch Centrum, Sittard, Netherlands
| | - C Fontaine
- Zaans Medisch Centrum, Zaandam, Netherlands; Universitair Ziekenhuis Brussel, Belgium; Catharina Ziekenhuis, Eindhoven, Netherlands; Clinique Notre Dame, Tournai, Belgium; Ziekenhuis Bernhoven, Oss, Netherlands; Salvatorziekenhuis, Hasselt, Belgium; Orbis Medisch Centrum, Sittard, Netherlands
| | - C Dopchie
- Zaans Medisch Centrum, Zaandam, Netherlands; Universitair Ziekenhuis Brussel, Belgium; Catharina Ziekenhuis, Eindhoven, Netherlands; Clinique Notre Dame, Tournai, Belgium; Ziekenhuis Bernhoven, Oss, Netherlands; Salvatorziekenhuis, Hasselt, Belgium; Orbis Medisch Centrum, Sittard, Netherlands
| | - A Vos
- Zaans Medisch Centrum, Zaandam, Netherlands; Universitair Ziekenhuis Brussel, Belgium; Catharina Ziekenhuis, Eindhoven, Netherlands; Clinique Notre Dame, Tournai, Belgium; Ziekenhuis Bernhoven, Oss, Netherlands; Salvatorziekenhuis, Hasselt, Belgium; Orbis Medisch Centrum, Sittard, Netherlands
| | - J Janssens
- Zaans Medisch Centrum, Zaandam, Netherlands; Universitair Ziekenhuis Brussel, Belgium; Catharina Ziekenhuis, Eindhoven, Netherlands; Clinique Notre Dame, Tournai, Belgium; Ziekenhuis Bernhoven, Oss, Netherlands; Salvatorziekenhuis, Hasselt, Belgium; Orbis Medisch Centrum, Sittard, Netherlands
| | - F. Erdkamp
- Zaans Medisch Centrum, Zaandam, Netherlands; Universitair Ziekenhuis Brussel, Belgium; Catharina Ziekenhuis, Eindhoven, Netherlands; Clinique Notre Dame, Tournai, Belgium; Ziekenhuis Bernhoven, Oss, Netherlands; Salvatorziekenhuis, Hasselt, Belgium; Orbis Medisch Centrum, Sittard, Netherlands
| |
Collapse
|
6
|
Machiels JH, Mazzeo F, Clausse M, Filleul B, Marcelis L, Honhon B, D’Hondt L, Dopchie C, Bonny M, Kerger J. Phase III trial of docetaxel (D), estramustine (E), and prednisone versus docetaxel plus prednisone in patients with metastatic hormone-refractory prostate cancer (HRPC). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.5067] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5067 Background: D alone or in combination with E improves survival of pts with metastatic HRPC. Whether E is necessary in combination with D is controversial. Preclinical data suggest a synergistic activity between D and E. Phase II as well as small randomized trials support this hypothesis, although indirect comparisons between the large phase III studies are not in favor of D/E combination. We conducted a randomized, prospective, multicentric study to compare D versus D/E. Methods: 150 metastatic HRPC were randomized (minimisation, stratification parameters: PSA level, ECOG, previous E use (38 pts), and center) between D (35 mg/m2 on day 2 and 9, every 3 wks) and D in combination with E (280 mg PO tid on days 1 to 5 and 8 to 12, coumadin 1mg/d). E was the only difference between the two treatment arms. All the pts received prednisone (10 mg/d). The primary endpoint was PSA response rate (decrease in PSA > 50% from baseline) and the study was powered to detect a 25% difference in PSA response rate. Results: No significant difference was found for PSA response (D/E: 50/68 (73%); D: 48/69 (69%)), time to PSA progression (median 205 days for D/E and 210 days for D), duration of PSA response (median 185 days for D/E and 220 days for D), progression-free survival (median 186 days for D/E and 195 days for D), response rate according to RECIST, and overall survival (median 617 days for D/E and 629 days for D). PSA < 4 ngr/mL occurred in 28/68 pts (41%) in D/E and in 17/69 (25%) in D (p=0.04). More pts had at least one grade 3/4 NCI-CTC toxicity in D/E (33/75 pts; 45%) compared to D (16/75 pts; 21%) (p=0.003). The main difference was grade 3/4 digestive toxicity (D/E:15% and D:4%; p=0.017). Serious adverse events were reported more frequently in D/E than D: 20 vs 9 (p=0.03). In D/E, the most frequent grade 3/4 toxicities were digestive (15%) and venous thrombosis (12%). In D, the most frequent grade 3/4 toxicity was anemia (9%) and venous thrombosis (8%). Conclusions: Our study did not show any clinically relevant advantage in term of efficacy for the addition of E to D. Both regimens were well-tolerated although the toxicity profile was in favor of D without E. Our study does not support the addition of E to D to treat pts with HPRC. [Table: see text]
Collapse
Affiliation(s)
- J. H. Machiels
- Medical Oncology, Universite catholique de Louvain, Brussels, Brabant, Belgium; Clinique Saint Luc, Bouge, Belgium; Hôpital de Jolimont, Haine-St–Paul, Belgium; CHIREC Site Parc Leopold, Brussels, Belgium; Hôpital St-Joseph, Gilly, Belgium; Clinique Notre Dame, Charleroi, Belgium; Clinique Notre Dame, Tournai, Belgium; UCL Mont-Godinne and St-Elisabeth, Yvoir and Namur, Belgium
| | - F. Mazzeo
- Medical Oncology, Universite catholique de Louvain, Brussels, Brabant, Belgium; Clinique Saint Luc, Bouge, Belgium; Hôpital de Jolimont, Haine-St–Paul, Belgium; CHIREC Site Parc Leopold, Brussels, Belgium; Hôpital St-Joseph, Gilly, Belgium; Clinique Notre Dame, Charleroi, Belgium; Clinique Notre Dame, Tournai, Belgium; UCL Mont-Godinne and St-Elisabeth, Yvoir and Namur, Belgium
| | - M. Clausse
- Medical Oncology, Universite catholique de Louvain, Brussels, Brabant, Belgium; Clinique Saint Luc, Bouge, Belgium; Hôpital de Jolimont, Haine-St–Paul, Belgium; CHIREC Site Parc Leopold, Brussels, Belgium; Hôpital St-Joseph, Gilly, Belgium; Clinique Notre Dame, Charleroi, Belgium; Clinique Notre Dame, Tournai, Belgium; UCL Mont-Godinne and St-Elisabeth, Yvoir and Namur, Belgium
| | - B. Filleul
- Medical Oncology, Universite catholique de Louvain, Brussels, Brabant, Belgium; Clinique Saint Luc, Bouge, Belgium; Hôpital de Jolimont, Haine-St–Paul, Belgium; CHIREC Site Parc Leopold, Brussels, Belgium; Hôpital St-Joseph, Gilly, Belgium; Clinique Notre Dame, Charleroi, Belgium; Clinique Notre Dame, Tournai, Belgium; UCL Mont-Godinne and St-Elisabeth, Yvoir and Namur, Belgium
| | - L. Marcelis
- Medical Oncology, Universite catholique de Louvain, Brussels, Brabant, Belgium; Clinique Saint Luc, Bouge, Belgium; Hôpital de Jolimont, Haine-St–Paul, Belgium; CHIREC Site Parc Leopold, Brussels, Belgium; Hôpital St-Joseph, Gilly, Belgium; Clinique Notre Dame, Charleroi, Belgium; Clinique Notre Dame, Tournai, Belgium; UCL Mont-Godinne and St-Elisabeth, Yvoir and Namur, Belgium
| | - B. Honhon
- Medical Oncology, Universite catholique de Louvain, Brussels, Brabant, Belgium; Clinique Saint Luc, Bouge, Belgium; Hôpital de Jolimont, Haine-St–Paul, Belgium; CHIREC Site Parc Leopold, Brussels, Belgium; Hôpital St-Joseph, Gilly, Belgium; Clinique Notre Dame, Charleroi, Belgium; Clinique Notre Dame, Tournai, Belgium; UCL Mont-Godinne and St-Elisabeth, Yvoir and Namur, Belgium
| | - L. D’Hondt
- Medical Oncology, Universite catholique de Louvain, Brussels, Brabant, Belgium; Clinique Saint Luc, Bouge, Belgium; Hôpital de Jolimont, Haine-St–Paul, Belgium; CHIREC Site Parc Leopold, Brussels, Belgium; Hôpital St-Joseph, Gilly, Belgium; Clinique Notre Dame, Charleroi, Belgium; Clinique Notre Dame, Tournai, Belgium; UCL Mont-Godinne and St-Elisabeth, Yvoir and Namur, Belgium
| | - C. Dopchie
- Medical Oncology, Universite catholique de Louvain, Brussels, Brabant, Belgium; Clinique Saint Luc, Bouge, Belgium; Hôpital de Jolimont, Haine-St–Paul, Belgium; CHIREC Site Parc Leopold, Brussels, Belgium; Hôpital St-Joseph, Gilly, Belgium; Clinique Notre Dame, Charleroi, Belgium; Clinique Notre Dame, Tournai, Belgium; UCL Mont-Godinne and St-Elisabeth, Yvoir and Namur, Belgium
| | - M. Bonny
- Medical Oncology, Universite catholique de Louvain, Brussels, Brabant, Belgium; Clinique Saint Luc, Bouge, Belgium; Hôpital de Jolimont, Haine-St–Paul, Belgium; CHIREC Site Parc Leopold, Brussels, Belgium; Hôpital St-Joseph, Gilly, Belgium; Clinique Notre Dame, Charleroi, Belgium; Clinique Notre Dame, Tournai, Belgium; UCL Mont-Godinne and St-Elisabeth, Yvoir and Namur, Belgium
| | - J. Kerger
- Medical Oncology, Universite catholique de Louvain, Brussels, Brabant, Belgium; Clinique Saint Luc, Bouge, Belgium; Hôpital de Jolimont, Haine-St–Paul, Belgium; CHIREC Site Parc Leopold, Brussels, Belgium; Hôpital St-Joseph, Gilly, Belgium; Clinique Notre Dame, Charleroi, Belgium; Clinique Notre Dame, Tournai, Belgium; UCL Mont-Godinne and St-Elisabeth, Yvoir and Namur, Belgium
| |
Collapse
|